切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2023, Vol. 17 ›› Issue (06) : 623 -626. doi: 10.3877/cma.j.issn.1674-3946.2023.06.011

论著

TK1、Ki67蛋白在分化型甲状腺癌组织中的表达及预后价值研究
江振剑, 蒋明(), 黄大莉   
  1. 571700 海南儋州,海南西部中心医院普外科
  • 收稿日期:2022-11-28 出版日期:2023-12-26
  • 通信作者: 蒋明

The expression and prognostic value of TK1 and Ki67 proteins in differentiated thyroid carcinoma

Zhenjian Jiang, Ming Jiang(), Dali Huang   

  1. Department of General Surgery, Hainan Western Central Hospital, Danzhou Hainan Province 571700, China
  • Received:2022-11-28 Published:2023-12-26
  • Corresponding author: Ming Jiang
  • Supported by:
    Hainan Provincial Health Industry Scientific Research Project(20A200169)
引用本文:

江振剑, 蒋明, 黄大莉. TK1、Ki67蛋白在分化型甲状腺癌组织中的表达及预后价值研究[J/OL]. 中华普外科手术学杂志(电子版), 2023, 17(06): 623-626.

Zhenjian Jiang, Ming Jiang, Dali Huang. The expression and prognostic value of TK1 and Ki67 proteins in differentiated thyroid carcinoma[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 623-626.

目的

探讨癌组织中胸苷激酶1(TK1)、细胞增殖抗原67(Ki67)蛋白表达与经乳晕入路腔镜辅助甲状腺切除术治疗的分化型甲状腺癌(DTC)患者预后的关系。

方法

采用病例对照研究,将2012年6月至2016年6月40例接受经乳晕入路腔镜切除术治疗预后不良的DTC患者,纳入预后不良组;将同期40例接受经乳晕入路腔镜切除术治疗预后良好的DTC患者,纳入预后良好组。所有患者完成5年随访。用SPSS 23.0软件进行数据处理,计数资料以[例(%)]表示,用χ2检验;等级资料用秩和检验;全部计量资料均经Shapiro-Wilk正态性检验,符合正态分布用()表示,组间比较采用独立样本t检验;偏态分布的计量资料用[M(P25,P75)]表示,组间比较用Mann-Whitney U检验;绘制受试者工作曲线(ROC)分析TK1、Ki67蛋白表达与DTC患者经乳晕入路腔镜切除术后预后的关系。以P<0.05为差异有统计学意义。

结果

DTC癌组织中TK1、Ki67蛋白阳性表达率(66.25%、71.25%)高于癌旁正常组织(21.25%、23.75%)(P<0.05);预后不良组患者甲状腺球蛋白(Tg)、促甲状腺激素(TSH)水平高于预后良好组,TK1、Ki67蛋白阳性表达率高于预后良好组(P<0.05);ROC曲线显示,TK1、Ki67蛋白表达预测经乳晕入路腔镜切除预后不良价值的AUC分别为0.825(95%CI: 0.728-0.922)、0.863(95%CI: 0.775-0.950),有一定预测价值。

结论

DTC患者预后与癌组织中TK1、Ki67蛋白表达有关。

Objective

To investigate the relationship between the expression of thymidine kinase 1(TK1) and cell proliferation antigen 67(Ki67) protein in cancer tissues and the prognosis of patients with differentiated thyroid carcinoma (DTC) treated by endoscopic assisted thyroidectomy via areola approach.

Methods

In a case control study, 40 DTC patients with poor prognosis who received endoscopic resection via areola from June 2012 to June 2016 were included in the poor prognosis group. At the same time, 40 patients with DTC with good prognosis who received endoscopic resection via areola approach were included in the good prognosis group. All patients were followed up for 5 years. SPSS 23.0 software was used for data processing. The enumeration data were expressed as [cases (%)], and χ2 test was used. Rank sum test was used for grade data; all measurement data were tested by Shapiro-Wilk normality test, and the normal distribution was expressed as (). Independent sample t test was used for comparison between groups. Measurement data with skewed distribution were expressed as [M(P25, P75)], and Mann-Whitney U test was used for comparison between groups. The receiver operating curve (ROC) was drawn to analyze the relationship between the expression of TK1 and Ki67 protein and the prognosis of DTC patients after endoscopic resection via areola approach. P<0.05 was considered statistically significant.

Results

The positive expression rate of TK1 and Ki67 protein in DTC cancerous tissues (66.25%, 71.25%) was higher than that in adjacent tissues (21.25%, 23.75%) (P<0.05); the levels of thyroglobulin (Tg) and thyroid stimulating hormone (TSH) in patients with poor prognosis were higher than those in patients with good prognosis, and the positive expression rates of TK1 and Ki67 protein were higher than those in patients with good prognosis (P<0.05). The ROC curve was drawn. The results showed that the AUC of TK1 and Ki67 protein expression predicting the poor prognosis of endoscopic resection via areola approach were 0.825 (95% CI: 0.728-0.922) and 0.863 (95% CI: 0.775-0.950), respectively, which had certain predictive value.

Conclusion

The prognosis of DTC patients may be related to the expression of TK1 and Ki67 proteins in cancer tissues, and TK1 and Ki67 proteins can be used as prognostic indicators of DTC patients.

图1 TK1在分化型甲状腺癌组织中的表达 注:A=癌组织中TK1蛋白强阳性(+++)表达(×200);B=癌组织中TK1蛋白弱阳性(+)表达(×400)。
图2 Ki67在分化型甲状腺癌组织中的表达(×200) 注:A=癌组织中Ki67蛋白强阳性(+++)表达;B=癌组织中Ki67蛋白阳性(++)表达。
表1 DTC患者癌组织、癌旁组织TK1、Ki67蛋白表达比较[例(%)]
表2 80例接受经乳晕入路腔镜甲状腺切除不同预后两组患者相关基线资料比较[例(%)]
图3 DTC患者癌组织TK1、Ki67蛋白表达预测经乳晕入路腔镜切除预后不良风险的ROC曲线图
[1]
Ito Y, Onoda N, Kudo T, et al. Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma[J]. In Vivo, 2021, 35(2): 1057-1064.
[2]
田文,姚京,郗洪庆,等. 中国腔镜甲状腺手术20年回顾与展望[J/CD]. 中华普外科手术学杂志(电子版), 2021, 15(06): 598-602.
[3]
石向阳,杨海波,韩江南. GAB1通过PI3K通路对甲状腺癌细胞增殖和淋巴管生成的影响[J]. 中国耳鼻咽喉头颈外科, 2020, 27(11): 615-618.
[4]
Lundgren POTribukait BKjellman A,et al. Serum thymidine kinase 1concentration as a predictive biomarker in prostate cancer[J]. Prostate, 2022, 82(8): 911-916.
[5]
Harbeck NRastogi PMartin M,et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67analysis from the monarchE study[J]. Ann Oncol, 2021, 32(12): 1571-1581.
[6]
中华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等. 甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华核医学与分子影像杂志, 2013, 33(02): 96-115.
[7]
Wong RM, Braunstein GD. Staging Systems for Differentiated Thyroid Carcinomas[M]. SpringerUS, 2012: 109-131.
[8]
文骝,庞士勇,李娟. 两种手术方式治疗甲状腺微小乳头状癌的安全性及近期预后比较[J/CD]. 中华普外科手术学杂志(电子版), 2021, 15(04): 447-449.
[9]
Schlumberger MLeboulleux S. Current practice in patients with differentiated thyroid cancer[J]. Nat Rev Endocrinol, 2021, 17(3): 176-188.
[10]
Knappe LGiovanella L. Life after thyroid cancer: the role of thyroglobulin and thyroglobulin antibodies for postoperative follow-up[J]. Expert Rev Endocrinol Metab, 2021, 16(6): 273-279.
[11]
Rianto BUDWibowo ASHerdini C. The Difference in Thyroid Stimulating Hormone Levels between Differentiated Carcinoma and Benign Enlargement[J]. Int Arch Otorhinolaryngol, 2020, 24(1): e73-e79.
[12]
祁亚宁,王利新,李刚. TSH及TG水平对甲状腺癌病程及预后评估价值[J]. 实用癌症杂志, 2020, 35(09): 1456-1459.
[13]
Jaamaa SNevala RJagarlamudi K,et al. Serum Concentration of Thymidine Kinase 1(TK1)as a Tumor Marker in Soft Tissue Sarcomas[J]. Anticancer Res, 2022, 42(3): 1509-1515.
[14]
McCartney AMalorni L. Thymidine kinase-1as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistance[J]. Biomark Med, 2020, 14(7): 495-498.
[15]
武鸿文,梅艳,王乔,等. 血清MIP-1α、S-TK1对于甲状腺癌术后放射性~(131)I治疗效果评估的临床价值[J]. 中国癌症杂志, 2021, 31(11): 1088-1095.
[16]
何时知,房居高,陈佳铭,等. 分化型甲状腺癌中CyclinD1,Galectin-3和ki-67的表达及其与侵袭的关系[J]. 河南师范大学学报:自然科学版, 2020, 48(02): 113-117.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 孙莲, 马红萍, 吴文英. 局部进展期甲状腺癌患者外科处理[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 112-114.
[6] 麻紫月, 王贞文, 张强, 赵代伟, 张翊伦. 右侧喉不返神经1例报告[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 115-116.
[7] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[8] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[9] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[10] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[11] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[12] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[13] 沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?